Resverlogix Corp. RFS.F Stock
Resverlogix Corp. Price Chart
Resverlogix Corp. RFS.F Financial and Trading Overview
| Resverlogix Corp. stock price | 0.03 EUR |
| Previous Close | 0.07 EUR |
| Open | 0.07 EUR |
| Bid | 0.07 EUR x 200000 |
| Ask | 0.08 EUR x 200000 |
| Day's Range | 0.07 - 0.07 EUR |
| 52 Week Range | 0.05 - 0.25 EUR |
| Volume | 185 EUR |
| Avg. Volume | 931 EUR |
| Market Cap | 19.37M EUR |
| Beta (5Y Monthly) | 0.633477 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RFS.F Valuation Measures
| Enterprise Value | 69.43M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.332 |
Trading Information
Resverlogix Corp. Stock Price History
| Beta (5Y Monthly) | 0.633477 |
| 52-Week Change | -50.00000000000000000000000000000000% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.25 EUR |
| 52 Week Low | 0.05 EUR |
| 50-Day Moving Average | 0.09 EUR |
| 200-Day Moving Average | 0.09 EUR |
RFS.F Share Statistics
| Avg. Volume (3 month) | 931 EUR |
| Avg. Daily Volume (10-Days) | 2.02K EUR |
| Shares Outstanding | 267.8M |
| Float | 176.27M |
| Short Ratio | N/A |
| % Held by Insiders | 44.27% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -78.97% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -10965000 EUR |
| Net Income Avi to Common (ttm) | -3610000 EUR |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 40K EUR |
| Total Cash Per Share (mrq) | 0 EUR |
| Total Debt (mrq) | 50.19M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.127 |
| Book Value Per Share (mrq) | -0.223 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3541000 EUR |
| Levered Free Cash Flow (ttm) | 599.63K EUR |
Profile of Resverlogix Corp.
| Country | Germany |
| State | AB |
| City | Calgary |
| Address | 4820 Richard Road SW |
| ZIP | T3E 6L1 |
| Phone | 403-254-9252 |
| Website | https://www.resverlogix.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
Q&A For Resverlogix Corp. Stock
What is a current RFS.F stock price?
Resverlogix Corp. RFS.F stock price today per share is 0.03 EUR.
How to purchase Resverlogix Corp. stock?
You can buy RFS.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Resverlogix Corp.?
The stock symbol or ticker of Resverlogix Corp. is RFS.F.
Which industry does the Resverlogix Corp. company belong to?
The Resverlogix Corp. industry is Biotechnology.
How many shares does Resverlogix Corp. have in circulation?
The max supply of Resverlogix Corp. shares is 312.46M.
What is Resverlogix Corp. Price to Earnings Ratio (PE Ratio)?
Resverlogix Corp. PE Ratio is now.
What was Resverlogix Corp. earnings per share over the trailing 12 months (TTM)?
Resverlogix Corp. EPS is -0.03 EUR over the trailing 12 months.
Which sector does the Resverlogix Corp. company belong to?
The Resverlogix Corp. sector is Healthcare.